Loading...
Please wait, while we are loading the content...
Similar Documents
Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Minkowitz, Harold S. Scranton, Richard Gruschkus, Stephen K. Nipper-Johnson, Kathy Menditto, Laura A. Dandappanavar, Akash |
| Copyright Year | 2014 |
| Abstract | BACKGROUND Opioid-related adverse drug events (ORADEs) are common causes of hospitalization and increased health care costs. OBJECTIVES To (a) estimate rates of specific adverse drug events (ADEs) among gastrointestinal (GI) surgery patients receiving postoperative opioids; (b) examine the utility of a risk-scoring model in categorizing patients at high risk of experiencing ORADEs; and (c) quantify potential clinical/economic benefits of targeting high-risk GI surgical patients for opioid-sparing regimens in terms of hospitalization cost, length of stay (LOS), and 30-day readmission rates. METHODS Using a retrospective design based on an administrative database, patients with an inpatient surgical procedure between January 1, 2010, and December 31, 2010, were included. GI surgical patients aged greater than 18 years followed from admission through 30 days postdischarge were characterized as high or low risk using clinical/demographic characteristics and were evaluated for several outcomes. Using multivariate logistic regression, the ORADE incidence, total hospitalization cost, LOS, and 30-day readmissions were compared for high-risk and low-risk patients. RESULTS In 87.8% (n = 3,235) of the surgical population, there was a strong concordance between risk assignment and ORADE incidence. Among the remaining 12.2% (n = 449) of patients, 5.5% (n = 202) were low risk with an ORADE, and 6.7% (n = 247) were high risk without an ORADE. Overall, 20.6% (n = 344) of high-risk patients experienced ≥1 ORADE (mean cost: $31,988; LOS: 12.1 days) compared with only 5.3% (n = 107) of low-risk patients (mean cost: $25,216; LOS: 8.0 days). High-risk patients had higher hospitalization costs and longer LOS than low-risk patients, respectively (mean cost: $19,234 vs. $13,036; mean LOS: 6.8 days vs. 3.3 days). These differences correspond to 47.0% higher costs for high-risk patients and an LOS approximately twice as long compared with low-risk patients. CONCLUSIONS Patient clinical/demographic characteristics influence the risk of developing ORADEs. Risk assessment tools can effectively identify high-risk patients, thereby enabling interventions that can reduce ORADEs, decrease hospital costs, and improve postsurgical experiences for patients. |
| Starting Page | 8 |
| Ending Page | 18 |
| Page Count | 11 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=18472 |
| PubMed reference number | 25166294v1 |
| Volume Number | 20 |
| Issue Number | 9 |
| Journal | Journal of managed care & specialty pharmacy |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Experience Gastrointestinal Diseases High Risk Acute Leukemia Hospitalization Patients Postoperative Complications benefit cellular targeting |
| Content Type | Text |
| Resource Type | Article |
